GYM329
- Generic Name
- GYM329
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
GYM329 is a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH-dependent manner
- Associated Conditions
- -
- Associated Therapies
- -
Spinal Muscular Atrophy Clinical Trials 2024 (Updated): EMA
DelveInsight's 'Spinal Muscular Atrophy Pipeline Insight, 2024' report details 18+ companies developing 20+ therapies, including key players like Scholar Rock, Biogen, and Roche. The report covers clinical trials, MOA, ROA, recent developments, and emerging therapies like ACTX-401, Apitegromab, and GYM329, expected to impact the SMA market.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath